DNTH - NASDAQ

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.97

-1.5%

HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.55B

EPS-4.2000

P/E Ratio-9.59

Earnings Date08/06/2026

dnth

Total Assets

Last Annual Value

530.92M

3-Year CAGR

86%

5-Year CAGR

27%

10-Year CAGR

47%

Adjust for Inflation

Dianthus Therapeutics, Inc. Competitors Analysis of Total Assets

DNTH · NASDAQ

Company	Total Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Dianthus Therapeutics, Inc. NASDAQ:DNTH	530.92M	43.6%	22.8%	46.9%
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	448.38M	1004.4%	399.4%	N/A
AnaptysBio, Inc. NASDAQ:ANAB	364.39M	-7.0%	-10.7%	19.3%
Nektar Therapeutics NASDAQ:NKTR	280.41M	-11.0%	-24.2%	-6.8%
Enliven Therapeutics, Inc. NASDAQ:ELVN	476.17M	20.5%	33.3%	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	416.89M	-9.7%	-18.1%	N/A
Tourmaline Bio, Inc. NASDAQ:TRML	309.00M	13.7%	4.2%	N/A
Taysha Gene Therapies, Inc. NASDAQ:TSHA	343.32M	25.7%	9.9%	N/A
Atai Beckley Inc. NASDAQ:ATAI	310.54M	1.9%	-5.6%	N/A

Dianthus Therapeutics, Inc. Fair Value Envelope

DNTH · NASDAQ

Our analysis suggests that DNTH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.97, this represents a potential HIDDEN relative to our calculated worth for Dianthus Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $84.97

Related Guides

Blog Categories

Continue your DNTH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.